Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cabometyx | Cabozantinib | HCC | Reimburse with clinical criteria and/or conditions | Complete | ||
Cabometyx | cabozantinib | Differentiated thyroid carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
TBD | Cabozantinib | Withdrawn | ||||
Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Active |